EGFR and non-small cell lung carcinoma: The recent approval of osimertinib as adjuvant monotherapy for EGFR-mutated stage IB-IIIA NSCLC suggests that, in the near future, other NSCLC driver mutations could be targeted in the adjuvant setting.